Indaptus Therapeutics to Present at JMP Securities Life Sciences Conference
June 09, 2022 07:00 ET
|
Indaptus Therapeutics
NEW YORK, June 09, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”), today announced that Jeffrey A. Meckler, Chief Executive Officer of Indaptus,...
Indaptus Therapeutics to Present at Jefferies Healthcare Conference
June 03, 2022 07:00 ET
|
Indaptus Therapeutics
NEW YORK, June 03, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”), today announced that Jeffrey A. Meckler, Chief Executive Officer of Indaptus,...
Indaptus Therapeutics Announces FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Decoy20 in Solid Tumors
May 19, 2022 07:00 ET
|
Indaptus Therapeutics
NEW YORK, May 19, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”), today announced that the U.S. Food and Drug Administration (FDA) has cleared the...
Indaptus Therapeutics to Present at H.C. Wainwright Global Investment Conference
May 18, 2022 16:15 ET
|
Indaptus Therapeutics
NEW YORK, May 18, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”) today announced that Jeffrey A. Meckler, Chief Executive Officer of Indaptus, will...
Indaptus Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 12, 2022 08:00 ET
|
Indaptus Therapeutics
Announces Submission of Investigational New Drug (IND) Application for Decoy20 On Track to Initiate Phase 1 Clinical Trial of Decoy20 for Treatment of Solid Tumors in Second Half of 2022 NEW YORK,...
Indaptus Therapeutics to Present at 2nd Annual Chronic HBV Drug Development Summit
April 20, 2022 07:00 ET
|
Indaptus Therapeutics
NEW YORK, April 20, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”) today announced that Michael J. Newman, Ph.D., Founder and Chief Scientific...
Indaptus Therapeutics to Present at Maxim Group 2022 Virtual Growth Conference
March 23, 2022 07:00 ET
|
Indaptus Therapeutics
NEW YORK, March 23, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”), today announced that Jeffrey Meckler, Chief Executive Officer, will participate...
Indaptus Therapeutics Reports Fourth Quarter and Year End 2021 Financial Results and Provides Corporate Update
March 21, 2022 07:00 ET
|
Indaptus Therapeutics
NEW YORK, March 21, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”), today announces financial results for the fourth quarter and year ended...
Indaptus Therapeutics to Present at 3rd Annual STING & TLR-Targeting Therapies Summit
March 17, 2022 07:00 ET
|
Indaptus Therapeutics
NEW YORK, March 17, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”), today announced that Michael J. Newman, Ph.D., Founder and Chief Scientific...
Indaptus Therapeutics to Present at 34th Annual ROTH Conference
March 07, 2022 07:00 ET
|
Indaptus Therapeutics
NEW YORK, March 07, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”), today announced that Jeffrey Meckler, Chief Executive Officer, will participate...